PMV Pharmaceuticals (PMVP)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- p53 Reactivationsrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 39/100 (MEDIUM), 13.8 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 6.48% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know
- PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors
- PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer
- PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push
- PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
- PMV Pharmaceuticals Reports Updated Rezatapopt Ovarian Cancer Data, Commences Offering
- PMV Pharma Announces Proposed Public Offering of Securities
- PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for PMV Pharmaceuticals.
Full PMVP Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.